Treatment completion in latent tuberculosis infection at specialist tuberculosis units in Spain

International Journal of Tuberculosis and Lung Disease

Volumn 14, Issue 6, 2010, Pages 701-707

  Anibarro, L ^a   Casas, S ^b,c   Paz Esquete, J ^a   Gonzalez, L ^b   Pena, A ^a   Guerra, M R ^b   Sande, D ^a   Calvino L ^a   Santin, Miguel ^b,c,d  

^a Complexo Hospitalario de Pontevedra   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d Service of Preventive Medicine Complexo Hospitalario de Pontevedra ^*  (Spain)

Author keywords

Adherence; Latent tuberculosis infection; Preventive treatment

Indexed keywords

ETHAMBUTOL; ISONIAZID; ISONIAZID PLUS RIFAMPICIN; PYRAZINAMIDE; RIFAMPICIN; RIFATER; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; FEMALE; GENDER AND SEX; HUMAN; IMMIGRATION; LATENT TUBERCULOSIS INFECTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SOCIAL ASPECT; SPAIN; TUBERCULOSIS; TUBERCULOSIS CONTROL; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL; FOLLOW UP; HOSPITAL; LATENT TUBERCULOSIS; MIDDLE AGED; MULTICENTER STUDY; PREVALENCE; TREATMENT OUTCOME;

ADULT; ANTITUBERCULAR AGENTS; FEMALE; FOLLOW-UP STUDIES; HOSPITALS, CHRONIC DISEASE; HUMANS; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; SPAIN; TREATMENT OUTCOME;

EID: 77952404795     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR 2000; 49 (RR-6): 1-51.
2. Grupo de trabajo del area TIR de SEPAR. [SEPAR guidelines. Guidelines for tuberculosis prevention]. Arch Bronconeumol 2002; 38: 441-451. [Spanish]
3. Ferebee S. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc 1970; 26: 28-106.
4. LoBue P A, Moser K S. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 2003; 168: 443-447.
5. Kwara A, Herold J, Machan J, Carter E. Factors associated with failure to complete isoniazid treatment for latent tuberculosis infection in Rhode Island. Chest 2008; 133: 862-868. (Pubitemid 351536859)
6. Anibarro L, Lires J, Iglesias F, et al. Social risk factors for non-compliance with tuberculosis treatment in Pontevedra [Spain]. Gac Sanit 2004; 18: 38-44.
7. Eidlitz-Markus T, Zeharia A, Baum G, Mimouni M, Amir J. Use of the urine color test to monitor compliance with isoniazid treatment of latent tuberculosis infection. Chest 2003; 123: 736-739. (Pubitemid 36315486)
8. Hanifa Y, Mngadi K, Lewis J, Fielding K, Churchyard G, Grant A D. Evaluation of the Arkansas method of urine testing for isoniazid in South Africa. Int J Tuberc Lung Dis 2007; 11: 1232-1236. (Pubitemid 350146306)
9. Sterling T. New approaches to the treatment of latent tuberculosis. Semin Respir Crit Care Med 2008; 29: 532-541.
10. Reichler M, Reves R, Bur S, et al. Treatment of latent tuberculosis infection in contacts of new tuberculosis cases in the United States. South Med J 2002; 95: 414-420. (Pubitemid 34286737)
11. Parsyan A, Saukkonen J, Barry M, Sharnprapai S, Horsburgh C J. Predictors of failure to complete treatment for latent tuberculosis infection. J Infect 2007; 54: 262-266. (Pubitemid 46238167)
12. Shieh F, Snyder G, Horsburgh C, Bernardo J, Murphy C, Saukkonen J. Predicting non-completion of treatment for latent tuberculous infection: a prospective survey. Am J Respir Crit Care Med 2006; 174: 717-721. (Pubitemid 44395341)
13. Pina-Gutiérrez J, Ferrer-Traid A, Arias C, Sala-Farré M, López-Sanmartín J. Adherence and effectiveness of the treatment of latent tuberculosis infection with isoniazid for 9 months in a cohort of 755 patients. Med Clin (Barc) 2008; 130: 165-171. (Pubitemid 351507886)
14. Martínez Sanchís A, Calpe Calpe J, Llavador Ros G, Ena Muñoz J, Calpe Armero A. Primary prevention and treatment of latent tuberculosis infection with isoniazid: efficacy of a control program, 1997-2002. Arch Bronconeumol 2005; 41: 27-33.
15. Young H, Wessolossky M, Ellis J, Kaminski M, Daly J S. A retrospective evaluation of completion rates, total cost, and adverse effects for treatment of latent tuberculosis infection in a public health clinic in central Massachusetts. Clin Infect Dis 2009; 49: 424-427.
16. Machado A Jr, Finkmoore B, Emodi K, et al. Risk factors for failure to complete a course of latent tuberculosis infection treatment in Salvador, Brazil. Int J Tuberc Lung Dis 2009; 13: 719-725.
17. Rodriguez Chamorro M A, Garcia-Jimenez E, Amariles P, Rodriguez Chamorro A, Faus M J. [Review of the test used for measuring therapeutic compliance in clinical practice]. Aten Primaria 2008; 40: 413-418. [Spanish]
18. Perry S, Hovell M F, Blumberg E, et al. Urine testing to monitor adherence to TB preventive therapy. J Clin Epidemiol 2002; 55: 235-238. (Pubitemid 34195518)
19. Hovell M, Blumberg E, Gil-Trejo L, et al. Predictors of adherence to treatment for latent tuberculosis infection in high-risk Latino adolescents: a behavioral epidemiological analysis. Soc Sci Med 2003; 56: 1789-1796.
20. Nyamathi A, Christiani A, Nahid P, Gregerson P, Leake B. A randomized controlled trial of two treatment programs for homeless adults with latent tuberculosis infection. Int J Tuberc Lung Dis 2006; 10: 775-782.
21. Kripalani S, Yao X, Haynes R. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med 2007; 167: 540-550. (Pubitemid 46513223)
22. Landry J, Menzies D. Preventive chemotherapy. Where has it got us? Where to go next? Int J Tuberc Lung Dis 2008; 12: 1352-1364.
23. Bieberly J, Ali J. Treatment adherence of the latently infected tuberculosis population (post-Katrina) at Wetmore TB Clinic, New Orleans, USA. Int J Tuberc Lung Dis 2008; 12: 1134-1138.
24. Ailinger R, Moore J, Nguyen N, Lasus H. Adherence to latent tuberculosis infection therapy among Latino immigrants. Public Health Nurs 2006; 23: 307-313. (Pubitemid 43990857)
25. Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman L. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest 2006; 130: 1712-1717. (Pubitemid 46033423)
26. Ailinger R, Dear M. Adherence to tuberculosis preventive therapy among Latino immigrants. Public Health Nurs 1998; 15: 19-24. (Pubitemid 128456535)
27. Mateus-Solarte J, Carvajal-Barona R. Factors predictive of adherence to tuberculosis treatment, Valle del Cauca, Colombia. Int J Tuberc Lung Dis 2008; 12: 520-526. (Pubitemid 351709869)
28. Geijo M, Herranz C, Vaño D, García A, García M, Dimas J. [Short-course isoniazid and rifampin compared with isoniazid for latent tuberculosis infection: a randomized clinical trial]. Enferm Infecc Microbiol Clin 2007; 25: 300-304. [Spanish]
29. Rennie T, Bothamley G, Engova D, Bates I. Patient choice promotes adherence in preventive treatment for latent tuberculosis. Eur Respir J 2007; 30: 728-735. (Pubitemid 351194834)
30. Martínez Alfaro E, Solera J, Serna E, et al. [Compliance, tolerance and effectiveness of a short chemoprophylaxis regimen for the treatment of tuberculosis]. Med Clin (Barc) 1998; 111: 401-404. [Spanish]
31. Page K, Sifakis F, Montes de Oca R, et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med 2006; 166: 1863-1870. (Pubitemid 44455169)
32. Spyridis N, Spyridis P, Gelesme A, et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis 2007; 45: 715-722. (Pubitemid 47378885)